She also directs the Glenn Foundation for Research on Aging at Princeton and the Simons Collaboration on Plasticity in the Aging Brain. She earned her PhD in Biochemistry from Stanford and completed postdoctoral training at UCSF in the genomics of aging. At Princeton, Dr. Murphy’s lab develops C. elegans models of human quality-of-life aging phenotypes, including cognitive and reproductive aging, and has identified genetic pathways that extend these processes across species. She is the author of How We Age: The Science of Longevity, a 2024 PROSE Finalist. Her honors include the NIH Director’s New Innovator Award, HHMI-Simons Faculty Scholar recognition, and two NIH Director’s Pioneer Awards.

She was on the founding team of Tally Health (acquired), where she developed and launched an epigenetic aging clock model and interventions within a year, while authoring 5 publications. She previously led 858 Therapeutics’ New York subsidiary and stayed on when Gotham was acquired; the lead asset is in the clinic with an FDA Fast Track designation. Earlier in her career, Dr. Cuellar discovered drug targets and co-developed widely cited technology platforms, such as a novel RNA delivery platform and CRISPR screening, at Genentech. Her expertise spans aging, oncology, CRISPR screening, RNA therapeutics, neurodegeneration, and regenerative medicine. She holds a PhD from UCSF and an MBA from MIT.

Dr. Kaletsky graduated from Rutgers University with a B.S. in Biotechnology, then received her PhD in Cellular & Molecular Biology at the University of Pennsylvania. Her work in the Murphy lab includes pioneering several genomics methods in C. elegans for the study of aging, and she carried out the first research on systemic signals for human reproductive aging in blood. Her focus is on molecular technology development, characterizing the molecular mechanisms of aging, and identifying aging interventions.

Ms. Dobbins graduated from Stanford University with a B.S. in Biomedical Computation and has been researching age-related diseases throughout her academic career. While at Stanford, she studied Huntington’s Disease in the Frydman Lab; after graduation, she worked at Denali Therapeutics on a clinical trial for Amyotrophic Lateral Sclerosis. At Princeton she is co-advised by Dr. Coleen Murphy and Dr. Olga Troyanskaya, developing new approaches for incorporation of non-linear information from blood for the study of reproductive aging.